Drug Shortage Report for IRBESARTAN HCT
Report ID | 126603 |
Drug Identification Number | 02385325 |
Brand name | IRBESARTAN HCT |
Common or Proper name | IRBESARTAN HCT |
Company Name | SIVEM PHARMACEUTICALS ULC |
Market Status | MARKETED |
Active Ingredient(s) | IRBESARTAN HYDROCHLOROTHIAZIDE |
Strength(s) | 300MG 12.5MG |
Dosage form(s) | TABLET |
Route of administration | ORAL ORAL |
Packaging size | 100 |
ATC code | C09DA |
ATC description | ANGIOTENSIN II ANTAGONISTS, COMBINATIONS |
Reason for shortage | Shortage of an active ingredient. |
Anticipated start date | |
Actual start date | 2020-10-12 |
Estimated end date | Unknown |
Actual end date | 2020-11-30 |
Shortage status | Resolved |
Updated date | 2021-02-12 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 4705 DOBRIN STREET SAINT-LAURENT, QUEBEC CANADA H4R 2P7 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v1 | 2020-10-16 | English | Compare |
v2 | 2020-10-16 | French | Compare |
v3 | 2021-02-12 | English | Compare |
v4 | 2021-02-12 | French | Compare |
Showing 1 to 4 of 4